Impact Events
Glittek Granites Board Approves Unaudited Q2 FY27 Results
Glittek Granites Limited announced the outcome of its Board Meeting held on October 29, 2026. The Board approved the unaudited financial results for the quarter and half-year ended September 30, 2026, along with the Limited Review Report. Additionally, the Board adopted revised policies and codes, including the Code of Conduct under SEBI (Prohibition of Insider Trading) Regulations, 2015. The company also provided an update on its land acquisition, noting the purchase of 23,780 Sq. Mtrs. in Gujarat for ₹26.50 crore.
Tonbo Imaging Secures EUR 65,000 Export Order from Europe
Tonbo Imaging India Ltd has received a strategic export order from a state-owned European company for its EO/IR stabilised seeker. The initial order is valued at approximately EUR 65,000 for First of Production Model (FOPM) units. Upon successful acceptance, the customer has the option to place a follow-on order potentially worth EUR 13 million. This order signifies the seeker's entry into an export loitering munition program and positions Tonbo for series supply. The company's CEO highlighted this as a validation of their investment in core imaging, stabilization, and tracking technology, enabling them to move from sensors into precision guidance. The contract is subject to an End User Certificate and export authorization from the Indian government.
Gujarat Inject Kerala Ltd to Raise ₹3 Cr via Equity Warrants
Gujarat Inject Kerala Ltd announced a Board Meeting outcome on October 29, 2026, wherein a proposal to raise funds up to ₹3,00,00,000 (Rupees Three Crore) through the issuance of 3,00,00,000 Equity Warrants on a preferential basis was approved. The company also proposed to increase its authorized share capital from ₹15,00,00,000 to ₹17,63,48,000 to facilitate this issuance. The warrants are convertible into equity shares of face value ₹1 each within 18 months of allotment. The preferential issue will be made to Non-promoter/Public Category investors, with the issue price determined as per SEBI ICDR Regulations. An Extra-Ordinary General Meeting (EGM) will be convened to seek shareholder approval for these proposals.
KIMS Hospitals Acquires 51% Stake in Sarvottam Healthcare for ₹79.5 Cr
Krishna Institute of Medical Sciences Ltd (KIMS) has entered into definitive agreements to acquire a 51% equity stake in Sarvottam Healthcare Private Limited for an aggregate consideration of up to ₹79.50 Crore (Rupees Seventy Nine Crore Fifty Lakhs only). Sarvottam Healthcare, operating as Trust Multi Speciality Hospital in Kakinada, has a current capacity of 183 beds and was incorporated in 2011. The acquisition is considered a strategic investment for KIMS, which has been providing O&M services to the target entity. The transaction does not fall under related party transactions, and no specific regulatory approvals are required. The acquisition is expected to be completed in due course.
KIMS Acquires 5.82% Stake in Ushahkal Abhinav Specialty Hospital
Krishna Institute of Medical Sciences Ltd (KIMS) has acquired a 5.82% stake in Ushahkal Abhinav Specialty Hospital LLP (Sangli) for an aggregate consideration of up to ₹15 Crore. The acquisition is a strategic investment in the healthcare sector. Ushahkal Abhinav Specialty Hospital LLP is a quaternary care facility with 316 beds, founded in 2022, and reported a turnover of ₹80.42 Crore in FY 2025-26 with a PAT of -₹23.59 Crore. This transaction does not involve related parties.
Dr Reddys Laboratories Earnings Call Transcript Filed
Dr Reddys Laboratories Ltd has filed the transcript of its earnings call for the quarter and half-year ended September 30, 2026. The call was conducted on October 23, 2026. The transcript is available on the company's website.
5paisa Capital: Income Tax Appeal Partly Allowed, Relief of ₹40.03 Cr
5paisa Capital Limited announced that its appeal against an Income Tax order for AY 2023-24 has been partly allowed. The original assessment order had made additions/disallowances aggregating to ₹42.90 crore. The appellate authority granted relief of ₹40.03 crore, leaving a disallowance of ₹2.87 crore. The company is confident in its documentation for the remaining disallowance and will pursue necessary actions. This outcome is substantially favorable, with no compensation or penalty imposed.
STL Networks: Monitoring Agency Report for Preferential Issue
STL Networks Ltd has submitted its Monitoring Agency Report for the quarter ended September 30, 2026, concerning the utilization of proceeds from its Rs. 108.00 crore preferential warrants issue. CARE Ratings Limited, the appointed monitoring agency, has reported no deviation from the stated objects of the issue. The report confirms that Rs. 2.00 crore has been utilized as per the offer document's objectives. The company has also reported increased losses of Rs. 99 crore in FY26 compared to Rs. 32 crore in FY25.
Sudarshan Pharma Declares Unaudited Q2 FY27 Financial Results
Sudarshan Pharma Industries Ltd has announced its unaudited standalone and consolidated financial results for the quarter and half-year ended September 30, 2026. The Board of Directors approved these results along with the Auditors' Limited Review Report at a meeting held today. The filing was made pursuant to Regulation 33 of the SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015.
Alldigi Tech Q2 FY27 PAT Up 50.9% to ₹26.6 Cr
Alldigi Tech Limited reported strong financial results for Q2 FY27, with Profit After Tax (PAT) surging 50.9% year-on-year to ₹26.6 Cr. Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) increased by 28.5% YoY to ₹46.3 Cr, and the EBITDA margin expanded significantly by 576 basis points to 30.2%. This improvement was driven by AI-led efficiencies and a favorable revenue mix. Revenue grew 4.0% YoY to ₹153.3 Cr. The Tech & Digital segment saw a 12.9% YoY revenue increase, while international BPM revenue grew 12.6% YoY. Operating Cash Flow also saw a healthy increase of 11.0% YoY to ₹37.1 Cr. The company also announced a proposed share buyback of ₹48 Cr at ₹1,000 per share, subject to shareholder approval. The CEO highlighted the successful shift to a technology-led model and continued investment in AI.
Prashant India Ltd Board Meeting on Nov 5 to Approve Q2 Results
Prashant India Ltd has announced that its Board of Directors will convene on Thursday, November 5, 2026, at 4:00 PM IST. The primary agenda item is to consider and approve the standalone unaudited financial statements for the quarter and half-year ended September 30, 2026. The meeting will also address any other business deemed necessary by the Chairperson.
RPG Life Sciences Q2 FY27 Revenue Surges 16.5% to ₹211.6 Cr
RPG Life Sciences announced its financial results for the quarter and half-year ended September 30, 2026. Revenue from Operations grew by 16.5% to ₹211.6 crore in Q2 FY27, crossing the ₹200 crore milestone. Gross margin expanded by 260 basis points. Adjusted EBITDA (excluding one-off costs) grew 15% to ₹50.1 crore, representing 23.7% of revenue. The Domestic Formulations business showed strong growth, ranking as the 4th fastest-growing company in IPM, with its flagship brand Naprosyn crossing ₹100 crore in sales. The company also made significant strides in its API business by transferring it to RPG Active Pharma and acquiring two API plants, expanding manufacturing capacity fivefold. The acquired sites are expected to contribute fully from Q3 onwards.
Sanofi India declares ₹75 interim dividend; details TDS process
Sanofi India Ltd announced an interim dividend of ₹75 per equity share for FY2026. The record date for this dividend is November 5, 2026. The company has also provided detailed information regarding the Tax Deducted at Source (TDS) process for both resident and non-resident shareholders, outlining the required documentation and procedures to ensure appropriate tax deduction. Shareholders are urged to update their details by the record date to facilitate accurate TDS application and dividend payment.
Praruh Technologies: H1 FY27 Revenue Up 378%, PAT Up 733%
Praruh Technologies Limited announced its unaudited financial results for the half year ended September 30, 2026. The company reported a significant surge in performance, with revenue from operations reaching ₹8,406.23 lakhs (₹84.06 crore), a 378% increase year-on-year. EBITDA grew by 482% to ₹1,133.66 lakhs (₹11.34 crore), with the EBITDA margin expanding to 13.49%. Profit after tax (PAT) saw a substantial rise of 733% to ₹818.43 lakhs (₹8.18 crore). The management highlighted strong growth momentum, ongoing pursuit of large-ticket opportunities, and a strategic shift towards becoming an AI-driven solutions provider with proprietary software development. The company aims to improve profitability and advance its OEM ambitions, with priorities including expansion across India, strengthening capabilities in defence, cybersecurity, and AI solutions.
Jyoti CNC Automation Board Meeting on Nov 3, 2026
Jyoti CNC Automation Ltd has announced that its Board of Directors will convene on November 3, 2026. The primary agenda for this meeting is to consider and approve the standalone and consolidated financial results, including the statement of assets & liabilities and cash flow statements, for the quarter and half-year ended September 30, 2026. This meeting is crucial for the company to formally present its financial performance to stakeholders.